| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Depreciation | - | 1,036 |
| Net loss | -117,579 | -76,913 |
| Depreciation | 1,559 | 1,000 |
| Stock-based compensation | 24,877 | 16,792 |
| Accretion of discount on marketable securities, net | 6,182 | 4,126 |
| Amortization of right-of-use asset | 132 | 85 |
| Prepaid expenses and other assets | 5,248 | 3,950 |
| Accounts payable | 575 | 2,707 |
| Accrued compensation | -2,058 | -4,420 |
| Accrued other expenses and other liabilities | -745 | -1,293 |
| Lease liability | -555 | -366 |
| Net cash used in operating activities | -105,224 | -70,448 |
| Maturities of marketable securities | - | 229,118 |
| Purchases of marketable securities | 452,941 | 385,942 |
| Sales of marketable securities | 51,452 | 38,650 |
| Maturities of marketable securities | 319,120 | - |
| Purchases of property and equipment | 183 | 94 |
| Net cash used in investing activities | -82,552 | -118,268 |
| Proceeds from issuance of common stock, net of offering costs | 187,362 | 187,362 |
| Exercise of stock options | 4,153 | 2,494 |
| Proceeds from employee stock purchase plan | 598 | 598 |
| Net cash provided by financing activities | 192,113 | 190,454 |
| Net change in cash and cash equivalents | 4,337 | 1,738 |
| Cash and cash equivalents at beginning of period | 41,666 | - |
| Cash and cash equivalents at end of period | 46,003 | - |
Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. (EWTX)